Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native children aged 9–14 years at 5 years after vaccination

• DOI: 10.1016/j.vaccine.2024.04.033
• Publication Date: 2024-04-15T14:35:12Z
• Authors: Bionca M. Davis; Ian Blake; Gitika Panicker; Elissa Meites; Gail Thompson; Jesse Geis; Dana Bruden; Marc Fischer; Rosalyn Singleton; Elizabeth R. Unger; Lauri E. Markowitz; Michael G. Bruce
• Keywords: Male; Adolescent; Alaska Natives; Papillomavirus Infections; Vaccination; Antibodies, Viral; Immunogenicity, Vaccine; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Immunoglobulin G; Humans; Female; Papillomavirus Vaccines; Child; Alaska

Persistent human papillomavirus (HPV) infection can cause anogenital and oropharyngeal cancers. Many HPV infections and HPV-associated cancers are vaccine-preventable. Studies suggest long-term persistence of vaccine-induced antibodies. However, data are limited among Alaska Native people.During 2011-2014, we enrolled Alaska Native children aged 9-14 years who received a 3-dose series of quadrivalent HPV vaccine (4vHPV). We collected sera at 1 month and 1, 2, 3, and 5 years post-vaccination to evaluate trends in type-specific immunoglobulin G antibody concentrations for the 4vHPV types (HPV 6/11/16/18).All participants (N = 469) had detectable antibodies against all 4vHPV types at all timepoints post-vaccination. For all 4vHPV types, antibody levels peaked by 1 month post-vaccination and gradually declined in subsequent years. At 5 years post-vaccination, antibody levels were higher among children who received 4vHPV at a younger age.Alaska Native children maintained antibodies against all 4vHPV types at 5 years post-vaccination.